+49 2066 50687-70

ALL News

pressEN
World Sepsis Day on 13th September: Study on a new, digital pathogen diagnostic tool is evaluated

At least 85,000 people die every year in Germany from Sepsis, the most severe course of an infectious disease - also known commonly as blood poisoning. World Sepsis Day on September 1 3rd draws attention to this. In the case of Sepsis, it is crucial to identify the respective pathogen early and reliably. However, the detection is often not successful with the methods commonly used today. In a maximum of 30 percent of cases, a pathogen is identified using classic blood culture, in sepsis patients who have already been treated with antibiotics often in less than 10 percent of the cases. For this reason, a German-wide project led by the Department of Anaesthesiology and Intensive Care Medicine at Essen University Hospital is investigating how patients can benefit from a new, digital method for identifying pathogens. At the beginning of August 2023, the recruitment phase of this study was completed, earlier than planned and the evaluation of the results started.

pressEN
DigiSep trial achieves next milestone: Over 200 sepsis patients now included

About a year ago, the recruitment phase of the trial "DigiSep - Optimization of sepsis therapy based on patient-specific digital precision diagnostics" started. Now the project, led by the Department of Anesthesiology and Intensive Care Medicine at the University Hospital Essen, has reached another important
milestone: since mid-March 2023, half of the planned 410 trial patients have been recruited. Only in February, 43 patients were added, so that the recruitment target can be reached as planned in summer 2023.

pressEN
Improved patient outcomes with fewer dialysis cases thanks to more precise diagnosis – Health insurance companies also see savings potential

Fortschritte in der Infektionsdiagnostik: Die Noscendo GmbH bietet mit ihrem DISQVER-Diagnoseverfahren die Möglichkeit, Infektionserreger im Rahmen einer Krankenhausbehandlung schneller und präziser zu bestimmen als bisher möglich. Das nutzt nicht nur Patientinnen und Patienten. Auch Krankenkassen sehen darin Einsparpotenziale, etwa wenn teure Folgebehandlungen wie Dialysen vermieden werden können.

newsEN
Heiner Dreismann joins Noscendo’s Board of Directors

Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors

pressEN
Mission: Saving patient lives

Noscendo is committed to supporting physicians, clinics and laboratories in their daily work in the field of pathogen detection and to provide therapy-relevant results that directly benefit patients. With its groundbreaking diagnostic platform DISQVER®, Noscendo helps save patients' lives through highly accurate pathogen detection.

abstractspublicationsEN
Fast identification of disseminated mucormycosis in hematooncologic patients by next-generation sequencing: a case series.

Invasive mucormycoses are increasingly emerging and a severe health threat with potentially fatal outcome especially for immunocompromised patients. They are challenging to diagnose: the diagnostic workup includes numerous tests, is time-intensive and frequently invasive. Cultivation is difficult and slow and yet frequently remains negative. Fast diagnosis for a timely treatment is urgently needed. We here describe a case series, where untargeted next-generation sequencing (NGS, with Noscendo’s CE-IVD marked DISQVER® pathogen test) provided identification of moulds in three patients with underlying hematologic malignancies from a standard blood draw within 24h after sample arrival.

abstractspublicationsEN
Pathogen detection by metagenomic next-generation sequencing during neutropenic fever in patients with haematological malignancies

Febrile neutropenia (FN) following chemotherapy is a major cause of morbidity requiring urgent use of broad-spectrum antibiotics. Blood culture (BC) is a standard diagnostic method for FN but sensitivity of pathogen detection is low. Timely identification of causative pathogens using metagenomic next-generation sequencing (mNGS) of circulating cell-free DNA (cfDNA) from plasma could reduce morbidity and costs by enabling early-targeted antimicrobial therapy. The aim of this study is to establish mNGS (DISQVER) for the detection of pathogens within 24h in immunocompromised haematological patients with FN

pressEN
SensID and Noscendo combine forces to develop a contamination-free reference material

SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve as process controls to ensure highest process quality and validity for patient samples.

pressEN
Faster pathogen identification with new method

In hospitals in Germany, infections are one of the greatest challenges. So-called sepsis, colloquially also known as blood poisoning, accounts for a major portion of these infections. According to a study by Jena University Hospital, nationwide 320,000 people develop sepsis, and one quarter of those affected die of the sequelae. This analysis implies that in the state of Rhineland-Palatinate almost 16,000 people will fall ill with sepsis each year. The faster and the more effectively the responsible germs can be fought, the faster the patient will recover. This also means that life-saving intensive care beds become available again more quickly, which is of major importance during the current corona pandemic. “Thanks to a new contract of Mainz University Medical Centre with software company Noscendo and TK health insurance, a new software-based method comprising a special test and a pathogen platform can now be used to identify the causative pathogens. This means that it is possible to help those insured with us more quickly and more effectively,” rejoices Jörn Simon, director of TK’s state office in Rhineland-Palatinate

pressEN
“Rapid results cure patients and relieve pressure on hospitals” – Noscendo’s Lab featured by BioRegioStern

Noscendo GmbH arrives at TTR in Reutlingen with innovative diagnostics platform Rapid results cure patients and relieve pressure on hospitals (Stuttgart/Reutlingen) – Noscendo GmbH recently opened a branch at the Reutlingen site of the Tübingen-Reutlingen Technology Park (TTR). Its state-of-the-art development and application laboratory identifies the causes of numerous infectious diseases exceptionally fast using next-generation sequencing (NGS) based on the company’s own diagnostics platform, which reliably detects bacteria, DNA viruses, fungi and parasites in patients’ blood samples. In intensive care medicine, obtaining…

pressEN
Noscendo closes series A financing and launches DISQVER® in Europe to significantly improve diagnosis of infectious diseases

Noscendo GmbH, a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections, today announced the commencement of operations in its own development and application laboratory as well as the closing of a financing round. Renowned new investors including Earlybird, Paua Ventures and the JIH Family Office joined the round while existing investors, such as Wieland Capital and High-Tech Gründerfonds, continued to invest.

pressEN
Noscendo expands proprietary diagnostic platform DISQVER® to include microbial resistances in partnership with University Hospital Bonn

Noscendo GmbH and the University Hospital Bonn (UKB) today announced the successful signing of a cooperative agreement with the Institute for Hygiene and Public Health (IHPH) at the UKB, working towards expansion of the proprietary and CE-certified diagnostic platform DISQVER® in the field of microbial resistances. Through the partnership, Noscendo GmbH will fully molecularly characterise up to 8000 antibiotic-resistant pathogens from over 35 species using the latest sequencing technology. The institute’s strain bank, which has been running for 20 years and is continually growing, and the environmental databank are fed from various national and international projects and their structure addresses significant resistance problems of today’s inpatient treatments.

pressEN
Noscendo reaches CE certification as key milestone for its proprietary diagnostic platform DISQVER® and conducts successful piloting in eight maximum care hospitals

Noscendo GmbH today announced the successful completion of the development of its proprietary diagnostic platform DISQVER® combined with corresponding CE certification as the first key milestone since the seed financing in October 2018. Noscendo’s platform detects bacteria, fungi, DNA viruses and parasites in the patient’s bloodstream on the basis of next-generation sequencing (NGS) and uses proprietary algorithms to assess the corresponding pathogen relevance

pressEN
Noscendo closes Financing Round for CE Certification and Market Entry Preparation of Platform Diagnostics for Bloodstream Associated Infections

In two-thirds of all cases, existing diagnostic procedures do not allow intensive care clinicians to draw conclusions on the pathogens causing bloodstream associated infections such as sepsis (“blood poisoning”) and endocarditis (inflammation of the inner layers of the heart). Therapy options are therefore very often limited to administering broad-band antibiotics. Unspecific therapy leads to high mortality rates and severe complications in many patients, and also accentuates the issue of resistant hospital pathogens.

Information for physicians

More precise diagnostics – more knowledge: Find out more about the clinical use of DISQVER!

How DISQVER works

Information for medical disciplines

Publications

News

Read more about Noscendo and DISQVER or visit us at trade fairs and conferences!

All News

Publications

Events

Press

Company

DISQVER together – get to know Noscendo!

Noscendo

Team

Advisory Board

Career